Alexion's Heart Drug Fizzles In Second Phase III CABG Study
Bad pre-holiday news from the Phase III trial with pexelizumab gave investors in Alexion Pharmaceuticals Inc. little cause to be thankful, and Wall Street took away more than a fourth of the stock's value. (BioWorld Today)